Skip to main content

When matters of the heart matter most, recommend TYLENOL®

TYLENOL® may be a good analgesic choice for patients with certain cardiovascular conditions1

92.1 million American adults have at least one type of cardiovascular disease2

When recommending an analgesic, it’s important to consider patients’ heart risks. The combination of certain pain relievers with some medicinal therapies can interfere with cardiovascular treatment. Because of its safety and analgesic efficacy, the American Heart Association has identified acetaminophen as a first-line pain relief option for patients with, or at high risk for, cardiovascular disease.3*

50 million American adults are on aspirin heart therapy4

Ibuprofen may inhibit aspirin’s cardioprotective benefits. Ibuprofen binds to the cyclooxygenase (COX-1) enzyme, which can interfere with aspirin’s ability to bind to COX-1 and exert its antiplatelet effect.1*

Watch ibuprofen interfere with aspirin’s cardioprotective benefits—and learn how TYLENOL® does not1

Aspirin binds to platelet COX-1 to inhibit platelet aggregation and to protect against myocardial infarction. Ibuprofen binds to the same area of the COX-1 enzyme. When a patient takes ibuprofen prior to taking aspirin, aspirin is blocked from reaching its binding sites.1 Adding an NSAID to aspirin can also increase the risk of stomach bleeding.5

TYLENOL® does not interfere with the cardioprotective benefits of aspirin the way ibuprofen can1

Visit the Resource Library to explore patient and practice support resources.

Cardiovascular Disease Icon

TYLENOL® is an appropriate analgesic choice to consider for patients on aspirin heart therapy1

Updated NSAID warnings: help your patients understand risks

The U.S. Food and Drug Administration (FDA) required an update to the Drug Facts labeling of all adult and pediatric non-aspirin OTC nonsteroidal anti-inflammatory drugs (NSAIDs), for example Motrin®, Advil®, and Aleve® products. These strengthen and expand existing warnings relating to the risk of heart attack and stroke associated with NSAIDs.6

TYLENOL® does not have a cardiovascular risk warning on its label

Download the NSAID Warning Comparison Guide for more information.

Get complimentary samples and coupons, condition-focused patient education, and more.

*When symptoms are not controlled by nonpharmacological approaches.

REFERENCES: 1. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817. 2. American Heart Association. Heart disease and stroke statistics 2017 at-a-glance. https://healthmetrics.heart.org/wp-content/uploads/2017/06/Heart-Disease-and-Stroke-Statistics-2017-ucm_491265.pdf. Accessed January 12, 2018. 3. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634-1642. 4. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease. JAMA. 2007;297(18):2018-2024. 5. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2008;118(8):1894-1909. 6. U.S. Food and Drug Administration. FDA strengthens warning of heart attack and stroke risk for non-steroidal anti-inflammatory drugs. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm453610.htm. Accessed January 12, 2018.  7. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: a cross-sectional study. BMJ Open. 2013;3(5):e002624.